Information  X 
Enter a valid email address

Company Name matching 'INVENTIVA'

Date
Time Source
Company
Announcement
23 May 2019 4:58 pm GNW   Factsheet INVENTIVA (0RNK) Repeat: Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH
  4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH
15 May 2019 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Q1 2019 Financial Information and Corporate Business Update
23 Apr 2019 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva to present new results of its YAP-TEAD oncology program at the AACR Special Conference on The Hippo Pathway
05 Mar 2019 4:47 pm GNW   Factsheet INVENTIVA (0RNK) INVENTIVA : The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI
27 Feb 2019 4:45 pm GNW   Factsheet INVENTIVA (0RNK) INVENTIVA: 2018 Full-Year Results : Important Progress in R&D Portfolio and Solid Cash Position
21 Feb 2019 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH
04 Feb 2019 4:45 pm GNW   Factsheet INVENTIVA (0RNK) INVENTIVA : New results on lanifibranor to be presented at the International Liver Congress 2019
10 Dec 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva invited to present at the 37th Annual J.P. Morgan Healthcare Conference
13 Nov 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva: 2018 third quarter financial update
07 Nov 2018 4:49 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva Announces Poster Presentation on Its YAP/TEAD Inhibitor Program at the EORTC-NCI-AACR Symposium in Dublin
17 Oct 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva announces two appointments to its management team ahead of future key development milestones
15 Oct 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva Announces Last Visit by Last Patient in its Phase IIb SSc Trial and Second Positive DSMB Review in its Phase IIb NASH Trial with Lanifibranor
12 Oct 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) INVENTIVA to Participate in the "ROTH Battle of the NASH Thrones Investor Conference"
10 Oct 2018 4:46 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference
27 Sep 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva: First-half 2018 financial results and business update
24 Sep 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) INVENTIVA : Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment
30 Aug 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) INVENTIVA advances in the development of lanifibranor with the achievement of three key milestones
23 Aug 2018 6:55 pm GNW   Factsheet Inventiva SA (0RNK) Inventiva S.A.: Sale of Shares
  5:43 pm GNW   Factsheet Inventiva SA (0RNK) Inventiva S.A.: Sale of Shares
22 Aug 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva announces that it has been informed of the modification of the call option agreement concluded by BVF Partners L.P.
13 Aug 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva's lanifibranor found to have good safety profile following first assessment of carcinogenicity studies' results
19 Jul 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva Reports First-half 2018 Financial Results and Provides a Corporate Update
20 Jun 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) INVENTIVA : FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease
04 Apr 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) INVENTIVA Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
07 Mar 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) INVENTIVA : 2017 Full Year Results - Major progress achieved in clinical development and strong cash position
26 Feb 2018 4:45 pm GNW   Factsheet INVENTIVA (0RNK) Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t